Sanofi takes a chance on Provention’s diabetes drug with marketing deal

The pharma will invest in the biotech and co-promote its drug teplizumab if the FDA OKs the medicine as a first-of-its-kind diabetes treatment.

By Kristin Jensen • Oct. 6, 2022

BioNTech to build an mRNA hub in Australia

A new agreement with the Australian government will bring messenger RNA research and manufacturing capabilities to the country, adding to the COVID-19 vaccine developer’s global expansion efforts. 

By Delilah Alvarado • Oct. 6, 2022

Explore the Trendline➔

Top 5 stories from BioPharma Dive

Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.

By BioPharma Dive staff

GSK immunotherapy matches Keytruda in lung cancer trial

The British drugmaker said a mid-stage study of its PD-1 inhibitor Jemperli alongside chemotherapy showed “positive headline” results, which it will present in full later.

By Kristin Jensen • Oct. 5, 2022

Takeda to stop making parathyroid drug Natpara in 2024 after production challenges

The Japanese drugmaker said it was unable to resolve manufacturing problems that led to a 2019 recall of the drug, which treats hypoparathyroidism.

By Christopher Newman • Oct. 4, 2022

Pfizer says PARP inhibitor succeeds in prostate cancer study

AstraZeneca paved the way for PARPs in prostate cancer when it won an approval for Lynparza in advanced patients. Now Pfizer may have a combination treatment for earlier-stage disease.

By Jonathan Gardner • Oct. 4, 2022

AstraZeneca to acquire gene editing biotech LogicBio

Shares in LogicBio had lost nearly all their value since a 2018 IPO, bringing the company to the brink of Nasdaq delisting. The buyout deal represents a premium of over 600%.

By Delilah Alvarado • Oct. 3, 2022

Building a bridge between science and medicine at Regeneron

Michael Klingler shares how the Biostatistics & Data Management team solve unsolvable problems together.

Oct. 3, 2022

Supreme Court grants Novartis request to halt Gilenya patent cancellation

The Swiss company said it would suffer irreparable harm if generics for the multiple sclerosis drug were allowed to enter the market before the higher court reviews the merits of its case.

By Christopher Newman • Sept. 30, 2022

[PODCAST] Evolution and Innovation in Oncology Therapeutics Development

The “Evolution and Innovation in Oncology Therapeutics Development” podcast series explores the role of multi-biomarkers in precision oncology.

By BioPharma Dive's studioID • Updated Sept. 11, 2023

J&J’s consumer health spinout to be named Kenvue

The planned split is a major shakeup for the world’s largest drugmaker and one of the most familiar corporate brands. The new company will sell well-known products like Tylenol and Band-Aids.

By Delilah Alvarado • Sept. 28, 2022

Biogen to pay $900M to settle lawsuit over MS drug outreach

A former Biogen employee sued in 2012, alleging the company paid physician fees to encourage prescribing of its drugs. Biogen did not admit wrongdoing as part of the settlement.

By Christopher Newman • Sept. 27, 2022

Roche pays $70M in another bid to catch up on cancer cell therapies

Rival companies have set a standard in lymphoma and leukemia. Now the Swiss drugmaker wants to be a pioneer in cell treatments for solid tumors.

By Jonathan Gardner • Sept. 27, 2022

Pfizer, BioNTech seek FDA clearance for updated COVID-19 booster in children

The request, if cleared, would make U.S. kids between 5 through 11 eligible to receive a "bivalent" shot targeting components of the omicron variants currently circulating. 

By Delilah Alvarado • Sept. 26, 2022

GSK names Julie Brown, former Burberry executive, its first female CFO

The U.K. drugmaker now also stands to become the first big pharmaceutical company to have women in its top two roles, with the transition planned for May 2023.

By Jonathan Gardner • Sept. 26, 2022

What biopharma companies can do to avoid a consumer communication crisis

Every challenge is also an opportunity. And these challenges offer biopharma companies an opportunity to improve communications in a way that also helps improve overall health.

Sept. 26, 2022

Health equity: the current environment and a path to improvement

Over the last 2 years, a greater spotlight has shone on inequalities in health care, and the greater need to improve health equity.

Sept. 26, 2022

Novartis warns of sales hit after federal court turns back patent appeal

The Swiss company is evaluating “all available options” following the ruling, which could lead to the launch of copycat versions of its MS drug Gilenya.

By Kristin Jensen • Sept. 21, 2022

J&J opens new research hub near San Francisco

The roughly 200,000-square-foot facility will house about 400 employees and more than double the size of the drugmaker’s presence in San Francisco.

By Delilah Alvarado • Sept. 20, 2022

Optimizing pharmaceutical innovation

Elevate pharma product development and marketing through collaboration with physician experts

Sept. 19, 2022

Sanofi, AstraZeneca secure EMA support for RSV drug in babies

If authorized by the European Commission, the companies’ antibody medicine would become the first cleared for broad use in newborns and infants. 

By Jonathan Gardner • Sept. 16, 2022

AstraZeneca claims positive results for its “add-on” drug for rare blood disease

The drug, meant to complement other treatments for paroxysmal nocturnal hemoglobinuria, comes via Alexion, which had acquired it from Achillion in 2019.

By Delilah Alvarado • Sept. 16, 2022

Pfizer reports success in trial of all-in-one meningitis vaccine

The company is planning an FDA submission as it works to expand its vaccine business beyond top-selling shots for COVID-19 and pneumonia.

By Jonathan Gardner • Sept. 15, 2022

Pfizer brings mRNA flu vaccine into Phase 3 testing

The trial, expected to enroll 25,000 adults, is the second late-stage test of an mRNA flu shot to begin this year, following the June start of a Moderna study.

By Delilah Alvarado • Sept. 14, 2022

Novartis funnels $300M into early biologic drug manufacturing

The investment is meant to improve Novartis’ capacity for developing and manufacturing biologic medicines that make up a larger share of its pipeline. 

By Christopher Newman • Sept. 12, 2022

Amgen data supports KRAS cancer drug, but survival benefit remains in question

Results from the company’s Phase 3 study show Lumakras outperformed chemotherapy. But that effect didn’t translate into patients living longer.

By Ned Pagliarulo • Sept. 12, 2022